^
Association details:
| Biomarker: | CD33 positive |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) + Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia
Published date:
11/04/2021
Excerpt:
This open-label multi-center phase 1b study evaluated the safety, tolerability, and preliminary response rates for Tala + GO in adult pts with CD33+ R/R AML….Three pts (50%) achieved a best response of complete response with incomplete count recovery (CRi) after 2 cycles....The overall response rate after 2 cycles of therapy was 50% (n=3, CRi).
Trial ID:
